Compare AIRE & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | BLRX |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 12.6M |
| IPO Year | 2023 | 2010 |
| Metric | AIRE | BLRX |
|---|---|---|
| Price | $2.01 | $3.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $1.30 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 70.0K | 29.1K |
| Earning Date | 04-28-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,518,498.00 | N/A |
| Revenue This Year | $129.06 | N/A |
| Revenue Next Year | $83.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 376.42 | N/A |
| 52 Week Low | $0.14 | $2.15 |
| 52 Week High | $3.98 | $5.05 |
| Indicator | AIRE | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.56 | 59.31 |
| Support Level | $1.89 | $3.07 |
| Resistance Level | $2.77 | $3.53 |
| Average True Range (ATR) | 0.19 | 0.24 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 12.30 | 81.15 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.